MedTrace Logo

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00195676 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1469

Last updated 2011-04-13

Study results available
· View outcomes & findings →

Summary

The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.

Conditions

Interventions

DRUG

adalimumab

40 mg every other week or 40 mg every week by subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Martin Okun, MD, PhD · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Poland
  • Puerto Rico
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195676 on ClinicalTrials.gov